Kilitch Drugs (India) Ltd Financials
Company Logo

Kilitch Drugs (India) Ltd Financial Statement

Kilitch Drugs (India) Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Jun 2024
Revenue36.63
Operating Expense30.20
Net Profit4.05
Net Profit Margin11.06
Earning Per Share2.52
EBIDTA6.16
Effective Tax Rate19.75

Kilitch Drugs (India) Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual131.60
Operating Expenses Annual111.28
Operating Profit Annual26.51
Interest Annual1.91
Depreciation1.24
Net Profit Annual17.57
Tax Annual5.78

Kilitch Drugs (India) Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning17.84
Cash Flow from Operations-11.19
Cash Flow from Investing-10.10
Cash Flow from Financing11.40
Cash Flow at the End7.95

Kilitch Drugs (India) Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)20.23
PBIT Margin (%)19.29
PBT Margin (%)9.75
Net PROFIT Margin (%)13.35
Return On Networth / Equity (%)8.39
Return On Networth /Employed (%)10.74
Return On Assets (%)7.48
Total Debt / Equity (X)0.13
Asset Turnover Ratio (%)0.56

Kilitch Drugs (India) Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual15.70
Total Current Assets Annual141.49
Non Current Assets Annual145.98
Total Shareholders Funds Annual222.92
Total Assets Annual287.47

Kilitch Drugs (India) Ltd Earning Calls

EPS (INR)

Expected

0.83

Reported

0.83

Surprise

0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.45%

Sep 2023

EPS beaten by 2.21%

Get Your FAQs Right

As of Nov 5, 2024, Kilitch Drugs (India) Ltd has a market capitalization of 626.97 Cr. Value Research classifies it as a Small-Cap company.
Yes, Kilitch Drugs (India) Ltd is debt-free with a debt-to-equity ratio of 0.14.
In FY 2023 , Kilitch Drugs (India) Ltd recorded a total revenue of approximately 131.60 Cr marking a significant milestone in the company's financial performance.
Kilitch Drugs (India) Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..
Kilitch Drugs (India) Ltd's current PE ratio is 35.68.
Kilitch Drugs (India) Ltd's ROCE averaged 8.9% from the FY ending March 2022 to 2024, with a median of 9.4%. It peaked at 9.9% in March 2024, reflecting strong capital efficiency over the period..
Kilitch Drugs (India) Ltd's latest EBIT is Rs. 25.26 Cr, surpassing the average EBIT of Rs. 20.10 Cr over the 5 years..